Pharma: Page 10

  • The dome of the U.S. Capitol Building as seen at dawn.
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    IRA reforms could be on the table. Will Trump and the GOP pursue them?

    Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

    By Amy Baxter • March 12, 2025
  • A sign reading Novo Nordisk is seen on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Novo’s Wegovy successor disappoints in second large trial

    A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly surpass Eli Lilly’s Zepbound.

    By • March 10, 2025
  • An illustration of beta amyloid plaques and tau in the brain Explore the Trendline➔
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Alzheimer's disease

    Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

    By BioPharma Dive staff
  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J scraps depression testing for potential blockbuster drug

    Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a drug from Neumora.

    By • March 7, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roche launches new Boston center; NIH centralizes peer review

    The Swiss pharma will base cardiometabolic drug research at the new Allston site. Elsewhere, AskBio, Bayer’s gene therapy subsidiary, advanced an experimental treatment for limb-girdle muscular dystrophy. 

    By BioPharma Dive staff • March 7, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy

    Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, the FDA cleared for testing a first-of-its-kind base editing therapy for Duchenne.

    By BioPharma Dive staff • March 6, 2025
  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    Bayer braces for ‘difficult’ year before turnaround pays dividends

    CEO Bill Anderson warned investors that profits will decline in 2025 before the company’s ongoing shake-up leads to an “improved trajectory” next year. 

    By Kristin Jensen • March 5, 2025
  • The HHS in DC
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Trump administration policies could create headwinds across healthcare: Fitch

    The administration’s initiatives could negatively impact the credit ratings of an array of companies, among them large drugmakers, Fitch said. 

    By Susanna Vogel • March 4, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Neumora bids farewell to R&D head; Biohaven’s ‘one step forward, one step back’ data

    Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff after shelving two cell therapy programs.

    By BioPharma Dive staff • March 4, 2025
  • Vials of Eisai and Biogen's new Alzheimer's drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip

    Leqembi, after delay, gets back on track toward EU approval

    European regulators “reaffirmed” a positive view of Eisai and Biogen’s Alzheimer’s drug after conducting a new safety review.

    By • Feb. 28, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Praxis hits trial setback; Bristol Myers lays off staff in New Jersey

    The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly struck a molecular glue deal and Zevra sold a priority review voucher.

    By BioPharma Dive staff • Feb. 28, 2025
  • A person speaks from a podium on stage, flanked by red banners.
    Image attribution tooltip
    Ned Pagliarulo/BioPharma Dive
    Image attribution tooltip
    Pharma reshoring

    Lilly CEO wields manufacturing plans to push pharma-friendly policies

    While announcing billions of dollars in new U.S. investments, David Ricks called for an extension of 2017 tax cuts and changes to Medicare's drug negotiation program.

    By Ned Pagliarulo • Feb. 26, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch

    The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a cancer biotech cut staff.

    By BioPharma Dive staff • Feb. 26, 2025
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Pharma reshoring

    Lilly expands US manufacturing build-out with $50B target

    The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry to reshore drug production.

    By Ned Pagliarulo • Feb. 26, 2025
  • A computer screen shows the Pfizer logo and stock price at the New York Stock Exchange
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Summit partners with Pfizer to study bispecific, ADC combinations

    The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially landscape-changing combinations.”

    By • Feb. 24, 2025
  • People pass an office building with signage spelling Pfizer in New York City.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer

    Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida Habtezion.

    By Ned Pagliarulo • Feb. 24, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair

    The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a competing bid for Acelyrin and Intra-Cellular sales rose.

    By BioPharma Dive staff • Updated Feb. 24, 2025
  • A Pfizer sign sits outside the company's Ian C. Read Laboratories in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Pfizer stops selling hemophilia gene therapy, citing weak demand

    Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.

    By Ned Pagliarulo • Feb. 21, 2025
  • Corporate logos are seen outside on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca deepens China presence with FibroGen deal

    The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through government investigations into its business practices there. 

    By Kristin Jensen • Feb. 20, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Sanofi reaches consumer health deal; Supernus antidepressant fails study

    The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Ultragenyx secured a PDUFA date for its Sanfilippo gene therapy.

    By BioPharma Dive staff • Feb. 19, 2025
  • A closeup of an entryway that reads the Federal Trade Commission.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    FTC retains stricter merger guidelines under Trump

    Agency chair Andrew Ferguson sent a memo to staff on Tuesday clarifying that Biden-era guidelines will remain in place — for now.

    By Rebecca Pifer • Feb. 19, 2025
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    GSK’s 5-in-1 meningococcal shot wins FDA approval

    Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through 25 years old.

    By • Updated Feb. 18, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

    Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

    By BioPharma Dive staff • Feb. 13, 2025
  • Robert F. Kennedy Jr. sitting with his name printed in front of a microphone in front of him with his arm extended besides him while speaking in a room with government officials in the background.
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip
    Trump administration

    RFK Jr. confirmed by Senate as health secretary

    All but one Senate Republican voted for Kennedy, a controversial vaccine critic whose embrace of the “Make America Healthy Again” movement helped him win one of the most powerful jobs in Washington.

    By , Emily Olsen • Feb. 13, 2025
  • A close up shot of glasses filled with liquid held close together for a toast.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    New study offers hints of GLP-1 drugs’ potential in curbing alcohol cravings

    A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed to establish a conclusive benefit.

    By • Feb. 12, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK

    The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

    By BioPharma Dive staff • Feb. 11, 2025